GTI-2040 and Gemcitabine in Treating Patients With Metastatic or Unresectable Solid Tumors

Phase 1

Completed

• Conditions: Unspecified Adult Solid Tumor, Protocol Specific
• Interventions: Biological: GTI-2040; Drug: gemcitabine hydrochloride; Other: laboratory biomarker analysis; Other: pharmacological study

• Registration Number: NCT00078962
• Lead Sponsor: National Cancer Institute (NCI)

Brief Summary

This phase I trial is studying the side effects and best dose of GTI-2040 and gemcitabine in treating patients with metastatic or unresectable solid tumors. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop tumor cells from dividing so they stop growing or die. GTI-2040 may stop the growth of tumor cells by blocking the enzymes necessary for their growth and by making tumor cells more sensitive to gemcitabine

Detailed Description

OBJECTIVES: Primary I. Determine the toxicity profile and maximum tolerated dose of GTI-2040 and gemcitabine in patients with metastatic or unresectable solid tumors.

Secondary I. Determine the pharmacokinetics and pharmacodynamics of this regimen in these patients.

OUTLINE: This is an open-label, dose-escalation study.

Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity.

Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.

PROJECTED ACCRUAL: Approximately 18-40 patients will be accrued for this study within 6-20 months.

Basic Information
|
Recruitment & Eligibility
|
Study & Design
|
Trial Locations

Study Timeline

• Study Start: 2004-01
• Study First Submitted: 2004-03-08
• Study First Submitted QC: 2004-03-08
• Study First Posted: 2004-03-09
• Primary Completion: 2007-11
• Status Verified: 2013-01
• Last Update Submitted: 2013-01-23
• Last Update Posted: 2013-01-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Histologically or cytologically confirmed solid tumor

  • Metastatic or unresectable disease for which standard curative or palliative measures do not exist or are no longer effective

• Measurable or evaluable disease

• No known active or progressive brain metastases or primary brain tumors

• Performance status - ECOG 0-2

• Performance status - Karnofsky 60-100%

• More than 12 weeks

• Hemoglobin > 9 g/dL

• Absolute neutrophil count ≥ 1,500/mm^3

• Platelet count ≥ 100,000/mm^3

• Bilirubin ≤ 2 times upper limit of normal (ULN)

• AST and ALT ≤ 3 times ULN (5 times ULN if hepatic metastases are present)

• Creatinine ≤ 2.0 mg/dL

• Creatinine clearance ≥ 50 mL/min

• No symptomatic congestive heart failure

• No unstable angina pectoris

• No cardiac arrhythmia

• Not pregnant or nursing

• Negative pregnancy test

• Fertile patients must use effective contraception

• No prior allergic reaction attributed to compounds of similar chemical or biological composition to study drugs

• No ongoing or active infection

• No psychiatric illness or social situation that would preclude study compliance

• No other condition (e.g., dementia or developmental delay) that would preclude giving informed consent

• No other concurrent uncontrolled illness that would preclude study participation

• Prior biologic therapy allowed

• No concurrent biologic therapy

• No concurrent immunotherapy

• No concurrent routine filgrastim (G-CSF) or sargramostim (GM-CSF)

• Prior gemcitabine allowed

• Prior investigational chemotherapy allowed

• At least 4 weeks since prior chemotherapy (6 weeks for mitomycin, carmustine, or nitrosoureas) and recovered

• No other concurrent chemotherapy

• Concurrent hormonal therapy (e.g., luteinizing hormone-releasing hormone agonists) for prostate cancer is allowed

• At least 4 weeks since prior radiotherapy and recovered

• No prior radiotherapy to more than 25% of bone marrow

• No concurrent radiotherapy

• Recovered from prior surgery

• No other concurrent investigational therapy

• No other concurrent anticancer therapy

• No concurrent combination antiretroviral therapy for HIV-positive patients

• No concurrent long-term oral anticoagulation therapy (e.g., warfarin)

  • Prophylactic warfarin to maintain central venous access patency allowed

Read More

Exclusion Criteria

Not provided

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Treatment (GTI-2040, gemcitabine hydrochloride)	GTI-2040	Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
Treatment (GTI-2040, gemcitabine hydrochloride)	gemcitabine hydrochloride	Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
Treatment (GTI-2040, gemcitabine hydrochloride)	laboratory biomarker analysis	Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.
Treatment (GTI-2040, gemcitabine hydrochloride)	pharmacological study	Patients receive GTI-2040 IV continuously on days 2-16 of course 1 and on days 1-16 of all subsequent courses and gemcitabine IV over 30 minutes on days 1, 8, and 15 of course 1 and on days 2, 9, and 16 of all subsequent courses. Courses repeat every 28 days in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of GTI-2040 and gemcitabine until the MTD is determined. The MTD is defined as the dose preceding that at which 2 of 3 or 2 of 6 patients experience dose-limiting toxicity. Once the MTD is determined, 10 additional patients are treated at that dose.

Primary Outcome Measures

Name	Time	Method
Maximum tolerated dose (MTD) of GTI-2040 and gemcitabine hydrochloride, graded according to the National Cancer Institute Common Toxicity Criteria (NCI CTC) v3.0	Up to day 28
Adverse events, graded according to the NCI CTC v3.0	Up to 2 years

Secondary Outcome Measures

Name	Time	Method
Levels of gemcitabine triphosphate (dFdCTP) in terms of pharmacokinetics of gemcitabine hydrochloride	Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)
Levels of ribonucleotide reductase R2 and protein expression	Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)	Student t-tests will be employed.
Levels of apoptotic markers and cell cycle regulatory proteins	Days 1, 2, 8, and 15 (course 1), days 1, 2, 9, and 16 (course 2)	Student t-tests will be employed.

Trial Locations

Locations (1)

Cancer Therapy and Research Center at The UT Health Science Center at San Antonio; 🇺🇸 San Antonio, Texas, United States